Announcements Trials
Browse Landscape

Phase

Phase 1 99Phase 2 47Phase 1/2 47Phase EARLY_PHASE1 13Phase 3 12Phase NA 10Phase 4 2Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 59Neoplasms 23Prostatic Neoplasms 20Multiple Myeloma 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 10Melanoma 9Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Pain, Postoperative 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Thyroid Neoplasms 5Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Tobacco Use Disorder 4

Interventions

zanubrutinib 1ibrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, B-Cell × 1 year × Clear all
NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
40 enrolled
LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Pharmacyclics Switzerland GmbH

Phase 4 Active not recruiting
297 enrolled
LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡